Plavix
NDC Package 16590-288-30

11-digit billing NDC: 16590028830

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Plavix is iNDICATIONS AND USAGEPLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows:Recent MI, Recent Stroke or Established Peripheral Arterial DiseaseFor patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Marketed by Stat Rx Usa Llc, this product is identified by NDC 16590-288 and is authorized under FDA application NDA020839.

Identification & Billing

NDC Package Code
16590-288-30
Package Description
30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
16590028830
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Plavix
Dosage Form
-
Usage Information
INDICATIONS AND USAGEPLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows:Recent MI, Recent Stroke or Established Peripheral Arterial DiseaseFor patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome- For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty

Regulatory & Marketing

Labeler Name
Stat Rx Usa Llc
FDA Application #
NDA020839
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-01-1900
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (16590-288). Click a package code to view its specific billing and regulatory data.

60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16590-288-30 identifies a specific commercial package of 30 tablet, film coated in 1 bottle, plastic of Plavix, labeled by Stat Rx Usa Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Stat Rx Usa Llc on January 01, 1900. The current certification is valid through December 31, 2017.

How is this Stat Rx Usa Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16590028830. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16590-288-30
11-Digit CMS (5-4-2)
16590-0288-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.